Global Preventive Vaccines Market Growth, Trends and Forecasts (2019-2024): AstraZeneca, Emergent BioSolutions, Daiichi Sankyo Co, GlaxoSmithKline, and Johnson & Johnson are Dominating – ResearchAndMarkets.com
March 29, 2019DUBLIN–(BUSINESS WIRE)–The “Global
Preventive Vaccines Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.
The global preventive vaccines market is currently recording a CAGR of
6.18%.
The preventive vaccines market has attained maturity in some of the
disease segments, like polio, while for some diseases, it is yet to
establish itself in the market. In spite of these differences in each
segment, the market is continuously experiencing growth, due to the
varying degrees of increase of the demand for vaccination for separate
diseases over time.
The growth of the global preventive vaccines market is due to the
increasing prevalence of infectious diseases, innovative technology in
vaccine development, increased funding from government and international
organizations, and increasing awareness on preventive care.
Infectious diseases are considered to be the world’s greatest killers
that pose some of the most significant health and security threats faced
by the global community. Various infectious diseases are among the
world’s leading causes of death.
Scientists from every country are currently performing research, sharing
information, building laboratory capacity in underdeveloped countries,
and creating global surveillance networks in order to prevent and
control their spread through preventive vaccinations.
However, healthcare costs are rising astronomically and the trends are
leaning toward prevention. The cost of vaccination has gone from a
single digit to even triple digits few times over the past two decades,
thus creating serious dilemmas for doctors and their patients, as well
as straining public health budgets.
Key Market Trends
Live/Attenuated Vaccines Segment is Expected to Exhibit Fastest
Growth Rate over the Forecast Period
Live/attenuated vaccines contain weakened versions of living microbes,
making them ineffective to cause diseases. These vaccines produce a
similar, yet weakened reaction, compared to that of natural infections.
The immune system generates strong cellular and antibody responses that
often confer lifelong immunity, with only one or two doses.
The live/attenuated vaccines need to be refrigerated to stay potent. In
addition, if the vaccine needs to be shipped overseas and stored by
healthcare workers, in developing countries that lack widespread
refrigeration, a live vaccine may not be the best choice.
Live/attenuated vaccines for certain viruses are relatively easy to
create.
Vaccines against measles, mumps, and chickenpox, among others, are
designed using this method. Pertaining to the ease of manufacturing, and
the ability to generate strong immune responses to the market for
live/attenuated vaccines, a steady growth rate is expected during the
forecast period.
North America Captured the Largest Market Share and is Expected to
Retain its Dominance
North America holds the largest share in the market, with the United
States being the largest contributor to its revenue. In the United
States, the Centers for Disease Control and Prevention’s (CDC) Advisory
Committee for Immunization Practices (ACIP) routinely publishes
recommendations for adult and childhood vaccination.
The United States has one of the leading healthcare systems in the world
and the vaccination coverage, in terms of vaccine inclusion, is at par
with the WHO guidelines. Thus, the preventive vaccine market in the
region is expected to show moderate growth over the forecast period.
Competitive Landscape
Some of the key players in the market are AstraZeneca PLC, Emergent
BioSolutions Inc., Daiichi Sankyo Co. Ltd, GlaxoSmithKline PLC, and
Johnson & Johnson, among others. These companies are also focusing on
innovations, and are spending majorly in R&D in order to lead the global
preventive vaccines market, thereby increasing competition among them.
Key Topics Covered
1 Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Infectious Diseases
4.2.2 Innovative Technology in Vaccine Development
4.2.3 Increased Funding from Government & International Organizations
4.2.4 Growing Awareness about Preventive Care
4.3 Market Restraints
4.3.1 Risk of Adverse Effects
4.3.2 Huge Capital Expenditures
4.4 Industry Attractiveness Porter’s Five Forces Analysis
5 Market Segmentation
5.1 By Vaccine Type
5.1.1 Live/Attenuated Vaccines
5.1.2 Inactivated Vaccines
5.1.3 Subunit Vaccines
5.1.4 Toxoid Vaccines
5.1.5 Conjugate Vaccines
5.1.6 Recombinant Vector Vaccines
5.1.7 DNA Vaccines
5.2 By Disease Type
5.2.1 Pneumococcal
5.2.2 Poliovirus
5.2.3 Hepatitis
5.2.4 Influenza
5.2.5 Measles, Mumps and Rubella (MMR)
5.2.6 Varicella
5.2.7 Human Papilloma Virus
5.2.8 Other Disease Types
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle East & Africa
5.3.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Emergent BioSolutions Inc.
6.1.3 Daiichi Sankyo Co. Ltd.
6.1.4 GlaxoSmithKline PLC
6.1.5 Johnson & Johnson
6.1.6 Merck & Co.
6.1.7 Novavax Inc.
6.1.8 Pfizer Inc.
6.1.9 Sanofi S.A.
6.1.10 Takeda Pharmaceutical Co. Ltd.
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/r/vq9ggl
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Vaccines